vs
Side-by-side financial comparison of Employers Holdings, Inc. (EIG) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $170.5M, roughly 1.8× Employers Holdings, Inc.). On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -21.3%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -11.4%).
Employers Holdings, Inc. is a U.S.-headquartered insurance holding company that specializes in offering workers' compensation insurance and customized risk management services primarily for small and medium-sized enterprises across the United States. It mainly serves clients in low-to-medium hazard industries, helping them mitigate workplace safety risks and meet relevant regulatory requirements for employee protection.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
EIG vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $170.5M | $311.4M |
| Net Profit | — | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | — | 16.4% |
| Revenue YoY | -21.3% | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $170.5M | $311.4M | ||
| Q4 25 | $188.5M | $295.9M | ||
| Q3 25 | $239.3M | — | ||
| Q2 25 | $246.3M | $317.0M | ||
| Q1 25 | $202.6M | $316.2M | ||
| Q4 24 | $216.6M | $297.0M | ||
| Q3 24 | $224.0M | $289.5M | ||
| Q2 24 | $217.0M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $-8.3M | — | ||
| Q2 25 | $29.7M | $-17.7M | ||
| Q1 25 | $12.8M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $30.3M | $33.6M | ||
| Q2 24 | $31.7M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | -4.7% | — | ||
| Q2 25 | 15.0% | -7.5% | ||
| Q1 25 | 7.8% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | 16.4% | 13.8% | ||
| Q2 24 | 18.4% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -3.5% | — | ||
| Q2 25 | 12.1% | -5.6% | ||
| Q1 25 | 6.3% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 13.5% | 11.6% | ||
| Q2 24 | 14.6% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.93 | $0.24 | ||
| Q3 25 | $-0.36 | — | ||
| Q2 25 | $1.23 | $-0.11 | ||
| Q1 25 | $0.52 | $0.14 | ||
| Q4 24 | $1.14 | $0.22 | ||
| Q3 24 | $1.21 | $0.21 | ||
| Q2 24 | $1.25 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.9M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $955.7M | $2.1B |
| Total Assets | $3.4B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $169.9M | $209.8M | ||
| Q4 25 | $169.9M | $172.9M | ||
| Q3 25 | $172.4M | — | ||
| Q2 25 | $78.1M | $162.2M | ||
| Q1 25 | $100.4M | $140.7M | ||
| Q4 24 | $68.4M | $177.5M | ||
| Q3 24 | $173.9M | $187.5M | ||
| Q2 24 | $126.4M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $19.0M | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $0 | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $955.7M | $2.1B | ||
| Q4 25 | $955.7M | $2.0B | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.1B | $2.0B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.1B | $2.1B | ||
| Q2 24 | $1.0B | $2.1B |
| Q1 26 | $3.4B | $2.6B | ||
| Q4 25 | $3.4B | $2.5B | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $3.5B | $2.6B | ||
| Q1 25 | $3.6B | $2.6B | ||
| Q4 24 | $3.5B | $2.7B | ||
| Q3 24 | $3.6B | $2.7B | ||
| Q2 24 | $3.5B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 0.00× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EIG
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
